|
Synonyms: AGEN-1181 | AGEN1181
Compound class:
Antibody
Comment: Botensilimab (AGEN-11810) is a Fc-enhanced anti-CTLA-4 monoclonal antibody [5]. It is proposed as an immuno-oncology agent for the treatment of poorly immunogenic and treatment refractory cancers [4,8]. Heavy and light chain peptide sequences for botensilimab are claimed in patent US10912831B1 [9], nominally SEQ IDs 25 and 27 respectively, and these are the chains of clone AGEN1884.H3 therein.
|
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 11659 | botensilimab |
Synonyms ![]() |
| AGEN-1181 | AGEN1181 |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1123 |
| Other databases | |
| GtoPdb PubChem SID | 530846838 |
| Search PubMed clinical trials | botensilimab |
| Search PubMed titles | botensilimab |
| Search PubMed titles/abstracts | botensilimab |